Sat, Aug 23, 2014, 9:07 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Financial News From Zacks Small Cap Research

  • On August 14, 2014, ULURU, Inc. (ULUR) reported financial results and filed its Form 10-Q for the second quarter ending June 30, 2014. ULURU classifies countries into four sizes:

  • NWTR: New Western Energy reports revenue gain of 840% and marked reduction in loss. Zacks Small Cap Research - Thu, Aug 21, 2014 10:00 AM EDT

    By Ian Gilson, PhD, CFA OTC:NWTR The company (OTC:NWTR) announced its second quarter results on August 18, 2014. Revenue was close to our estimate and increased by 840% Y/Y and 57% from the first quarter. ...

  • FPMI: Positive CardioPET Data. Q2 Results Zacks Small Cap Research - Wed, Aug 20, 2014 1:05 PM EDT

    Q2 operating expenses were ~$1.2M, slightly better than our $1.5M estimate.  We continue to expect operating expenses to increase with clinical trials progression.  Q2 net loss and EPS, excluding non-cash securities and derivative related items, were $1.4M and ($0.05), compared to our $1.7M and ($0.06) estimates.  Cash …

  • Zacks Small Cap Research Upgrades CUR Media to a BUY Zacks Small Cap Research - Wed, Aug 20, 2014 11:55 AM EDT

    OBB:CURM Zacks Analyst Lisa Thompson, has upgraded CUR Media (OBB:CURM) to a buy rating due to increased float and attractive valuation: PLEASE CLICK HERE FOR A FULL COPY OF THE RESEARCH REPORT. SUBSCRIBE ...

  • AEMD: Q1 Update, Revived Attention on Ebola Zacks Small Cap Research - Wed, Aug 20, 2014 9:15 AM EDT

    Aethlon Medical (AEMD) filed their 10-Q for the fiscal first quarter ending 6/30/2014.  Highlights in the quarter include further progress in cleaning up the balance sheet via the conversion of non-performing debt to equity and revived attention as to the potential utility of Hemopurifier in the treatment of pandemic threats, …

  • BPTH: Bio-Path Reports 2Q2014 Financials Zacks Small Cap Research - Tue, Aug 19, 2014 11:10 AM EDT

    On August 18, Bio-Path Holdings (BPTH) announced operational and financial results for the second quarter ended June 30, 2014. R&D expenses were $0.52 million for 2Q14, compared to $0.19 million for 2Q13, an increase of $361,004 primarily due to an increase of $233,985 in drug material expense for use in the clinical trial, …

  • Last week, Labor Smart (LTNC) announced results for 2Q 2014, with revenue of $6.43 million up 59.5% year-over-year. As a result, Labor Smart’s 2Q 2014 gross margin came in at 21.2%, a more than 600 basis point expansion year-over-year. The company’s goal is to drive further gross margin improvements. This compares to …

  • This offers a better access to Canadian capital markets and investors.  On May 13, 2014, Tribute entered into an exclusive license agreement with Faes Farma, S.A. (“Faes”), a Spanish pharmaceutical company, for the exclusive rights to sell Bilastine (inclusive of prescription and non-prescription for adults and pediatric …

  • GRDH: Guardian 8 reports 2Q – Awaiting catalyst for large-scale adoption of Pro V2 Zacks Small Cap Research - Mon, Aug 18, 2014 3:00 PM EDT

    On August 14, 2014, Guardian 8 Holdings (GRDH) reported financial results for the second quarter ending June 30, 2014. Guardian 8 generated revenues of $13,967 from the sales of G8 Pro V2 devices, which continue to be sold in small batches for modest deployments and evaluation. In mid-April, Guardian 8 announced that …

  • CTTC: Q2 Results. Court Ruling Favors Calmare Reimbursement Zacks Small Cap Research - Mon, Aug 18, 2014 2:15 PM EDT

    Q2 revenue of $332k compares to our $309k estimate and includes $316k from the sale of four Calmare units during the quarter.  Three units were sold to the private sector and one to the U.S. military.  Compared to Q2 2013 product sales and total revenue increased by 132% and 121%, respectively.  Through the first six months …

  • NHC.TO: Northstar Healthcare reports 2Q; Zacks raises target to $2.25 Zacks Small Cap Research - Mon, Aug 18, 2014 9:45 AM EDT

    On August 14, 2014, Northstar Healthcare (NHC.TO) reported financial results for the second quarter ending June 30, 2014. Net patient service revenue increased 158% to $15.11 million compared to $5.86 million in the second quarter of 2013, primarily due to increases in case volume, which was driven by marketing campaigns …

  • NHC.TO: Northstar Healthcare reports 2Q; Zacks raises target to $2.35 Zacks Small Cap Research - Mon, Aug 18, 2014 9:00 AM EDT

    On August 14, 2014, Northstar Healthcare (NHC.TO) reported financial results for the second quarter ending June 30, 2014. Net patient service revenue increased 158% to $15.11 million compared to $5.86 million in the second quarter of 2013, primarily due to increases in case volume, which was driven by marketing campaigns …

  •  On August 12, 2014, Arrowhead Research Corporation (ARWR) announced financial results for its fiscal 2014 third quarter ended June 30, 2014 and provided an update on the Phase IIa study of ARC-520.

  • PBIO: Product and Services Revenue for 2Q14 Continued to Grow Zacks Small Cap Research - Mon, Aug 18, 2014 7:00 AM EDT

    Sales of consumables were $48,417 for 2Q14, compared to $26,034 for the same period in 2013, an increase of 86%. Total revenue for 2Q14 was $307,464, compared to $357,736 for the same period in 2013, a 14% decrease. Sales of consumables were $103,029 for the six months ended June 30, 2014 compared to $53,258 for the same …

  • By Ann Heffron, CFA, CPA NASDAQ:QCRH Compared to the year-ago quarter, QCR Holdings, Inc.’s (NASDAQ:QCRH) second quarter net earnings after preferred stock dividends rose 12% to $3.6 million from $3.2 ...

  • ENSV: Zack raises target on Enservco on details of capacity expansion’s timetable Zacks Small Cap Research - Fri, Aug 15, 2014 9:00 AM EDT

    In the 10-Q and conference call, management provided an update on Phase 2 of the company’s 2014 capacity expansion plan, along with details of the new $40 million credit facility with PNC Bank, a fraction of will fund Phase 2. The new frac-water "mega" heaters have twice the capacity of the company's legacy frac-water …

  • ILIU: PerioPredict Roll-Out Progressing Zacks Small Cap Research - Fri, Aug 15, 2014 8:00 AM EDT

    Interleukin Genetics (ILIU) reported financial results for the second quarter ending June 30, 2014.  Results continue to come in largely in-line with our numbers with a slight beat in the quarter on both the top and bottom lines.  The company also continues to do a good job with efficiently managing resources in the initial …

  • APDN: An Emerging Market Leader in the Counterfeiting Industry Zacks Small Cap Research - Thu, Aug 14, 2014 11:45 AM EDT

    Total revenue for the third quarter of fiscal 2014 was $841,197, the highest revenues reported in the history of the Company.

  • BLU.TO: With Kiacta Phase 3 Fully Enrolled, Bellus Is Looking Attractive Zacks Small Cap Research - Wed, Aug 13, 2014 9:15 PM EDT

    On August 13, 2014, Bellus Health, Inc. (BLU.TO) announced financial results for the second quarter of 2014. Revenues for the quarter totaled $0.42 million, compared to $0.38 million in the corresponding period of 2013, and consisted mostly of revenue recognized for accounting purposes from the asset sale and licensing …

  • CTSO: Another Product Sales Record. Data Supports Cardiac Surgery Zacks Small Cap Research - Wed, Aug 13, 2014 3:30 PM EDT

    CytoSorbents Corp (CTSO) reported results for the second quarter ending June 3, 2014.  Product sales set a new all-time record and have now increased on a sequential basis every quarter except one since Q3 2012 (i.e. - 6 of the last 7 quarters).  The fuel behind the growth in product sales has remained consistent, that …

  • BCLI: Brainstorm Moves Into Phase 2 ALS Trial Zacks Small Cap Research - Wed, Aug 13, 2014 3:15 PM EDT

    On August 12, 2014, Brainstorm Cell Therapeutics, Inc. (BCLI) announced financial results and filed its  Form 10-Q  for the second quarter of 2014. Brainstorm exited the second quarter with approximately $11.3 million in cash and cash equivalents, compared with $3.5 million at the end of 2013. The cash position was bolstered by …

  • Soligenix (SNGX): Conservative Cash Burn Coupled With Non-dilutive Financing Zacks Small Cap Research - Wed, Aug 13, 2014 12:45 PM EDT

    On Aug. 11, 2014, Soligenix (SNGX) announced its financial results for the second quarter ended June 30, 2014. The $0.8 million in revenue increase was primarily related to contracts with the US Department of Health and Human Service's Biomedical Advanced Research and Development Authority (BARDA) and the National Institute …

  • Dejour Energy (DEJ) Update: 2nd quarter results & Unit offering Zacks Small Cap Research - Wed, Aug 13, 2014 9:00 AM EDT

    Last week, Dejour Energy (DEJ:NYSE) reported results for the second quarter ending June 30, 2014. Gross oil and gas revenues (before royalties) increased 2.8% Year-Over-Year (YOY) to $2.60 million, which was driven by the contribution of the first 4 Kokopelli wells which was partially offset by lower production at Woodrush. …

  • PRTX: Protalex Seeking Orphan Indication, Further Studies with PRTX-100 Zacks Small Cap Research - Tue, Aug 12, 2014 3:25 PM EDT

    On August 5, 2014, Protalex, Inc. (PRTX) reported financial results and filed its Form 10-K for the fourth quarter and full year Fiscal 2014 that ended May 31, 2014. As expected, Protalex did not report any revenues in the quarter. Net loss for the fourth quarter totaled $3.8 million, and was comprised of $0.78 million …

  • CEMI: Record DPP Sales Drive 38% Revenue Growth Zacks Small Cap Research - Tue, Aug 12, 2014 3:15 PM EDT

    Chembio (CEMI) reported results for the second quarter ending 6/30/2014.  Q2 revenue of $7.4M was up 37.6% from the comparable period in 2013 with product sales up 43.2%.  On a sequential basis, total revenue and product revenue increased by 27.6% and 47.8%, respectively.  The relative strong growth is even more impressive …

  • SNWV: DMC Evaluation Expected In September Zacks Small Cap Research - Tue, Aug 12, 2014 2:15 PM EDT

    Importantly, SNWV continues to maintain their predetermined timelines related to the dermaPACE supplemental clinical trial including for patient enrollment, treatment and follow-up, and data analysis.  This includes the continued expectation that feedback from the Data Monitoring Committee on the 90 patients required for …

  • Sorrento (SRNE): Valuation Is Attractive Zacks Small Cap Research - Tue, Aug 12, 2014 11:30 AM EDT

    ·      Sorrento (SRNE) reports 2Q14 financials; ·      Balance sheet remains strong; ·      Cynviloq enters into pivotal BE trial; ·      Draft registration filed for Ark Animal Therapeutics IPO;

  • CPKF: Second Quarter Better than Our EPS Estimate Zacks Small Cap Research - Mon, Aug 11, 2014 4:33 PM EDT

    By Ann Heffron, CFA, CPA OTC:CPKF Chesapeake Financial Shares, Inc.’s (OTC:CPKF) second quarter net earnings rose $0.1 million, or 5%, to $1.9 million, while diluted EPS grew by $0.03, or 5%, to $0.58 ...

  • TNXP: Tonix Fundamentals Remain Strong Zacks Small Cap Research - Mon, Aug 11, 2014 3:15 PM EDT

    On August 11, 2014, Tonix Pharmaceuticals (TNXP) reported financial results for the second quarter for the period ending June 30, 2014. The primary driver was increased development work related to TNX-102 SL, including manufacturing, preclinical, and human efficacy studies in fibromyalgia (FM). We remind investors that …

  • DRNE: Drone Aviation is Well-Positioned in the Tethered Aerostat Industry Zacks Small Cap Research - Mon, Aug 11, 2014 8:45 AM EDT

    ·         Drone Aviation Holding Corp. is a highly focused, tethered aerostat company ·         Management is focused on executing its strategy of penetrating new commercial markets ·         Investors should be closely monitoring Drone Aviation for the announcement of new BiB orders With headquarters in Jacksonville, …

  • BLFS: Q2 Results: Core Products Revenue Remains Strong Zacks Small Cap Research - Fri, Aug 8, 2014 8:00 PM EDT

    Q2 Results: Core Products Revenue Remains Strong, Look For Total Revenue To P/U Later in 2014…  BioLife Solutions (BLFS) announced results for Q2 2014.  While revenue and gross margin were largely in-line with our estimates, operating expenses came in meaningfully higher - at least a portion of which management indicated …

  • CDTi launched a new initiative on Aug. 5, 2014, the DuraFitTM  line of replacement diesel particulate filters (DPF). A DPF has a lifetime of about five years so this is a sustainable market for CDTi.

  • NBIX: Neurocrine To Move Tardive Dyskinesia Drug Into Phase 3 Zacks Small Cap Research - Fri, Aug 8, 2014 3:55 PM EDT

    On August 7, 2014, Neurocrine Bio (NBIX) reported financial results for the second quarter of 2014. The company reported no revenues for the quarter, as was expected. The company reported a net loss of $13.4 million ($0.18 per share) for the quarter, roughly in line with our expectation.  The company's balance sheet …

  • CUR: Neuralstem Pipeline Rolling Forward, Tackling Major Unmet Needs Zacks Small Cap Research - Fri, Aug 8, 2014 3:30 PM EDT

    On August 8, 2014, Neuralstem Inc. (CUR) reported financial results for the second quarter ending June 30, 2014. As of June 30, 2014, Neuralstem reported cash and investments of approximately $30.2 million.

  • DRRX: Durect Corp. Offers Favorable Risk / Reward Zacks Small Cap Research - Fri, Aug 8, 2014 3:30 PM EDT

    On August 7, 2014, Durect Corp. (DRRX) reported financial results for the second quarter ending June 30, 2014. During the second quarter of 2014, the company continued work on several feasibility projects and has multiple discussions underway with other parties about new feasibility projects utilizing the company’s proprietary …

  • CPXX: Celator Exited Second Quarter With A Strong Balance Sheet Zacks Small Cap Research - Fri, Aug 8, 2014 11:10 AM EDT

     ·      Celator exited 2Q14 with a strong balance sheet; On August 7, Celator (CPXX) reported financials for the second quarter ended June 30, 2014.

  • AMERCO (UHAL) announced its first quarter results of fiscal 2015 on Aug. 6, 2014 followed by a conference call on Aug. 07, 2014. Moving and Storage revenue grew by over 11%, which is a record for any 1Q/1Q period in company history. The rapid growth of U-Box required a new Point of Sale system which had a negative impact …

  • NVIV: Financial & Business Update On InVivo Therapeutics Zacks Small Cap Research - Thu, Aug 7, 2014 3:30 PM EDT

    On August 6, 2014, InVivo Therapeutics (NVIV) reported financial results for the second quarter ended June 30, 2014. We remind investors that on May 9, 2014, InVivo completed an underwrittenpublic offering whereby the company sold 14.0 million shares of common stock at $1.15 per share to raise gross proceeds of $16.1 million. …

  • POZN: Solid Second Quarter Financial Results Keep Us Bullish On Pozen Zacks Small Cap Research - Thu, Aug 7, 2014 3:15 PM EDT

    On August 7, 2014, Pozen, Inc. (POZN) reported financial results for the second quarter ended June 30, 2014. Total revenues in the quarter were $7.4 million, comprised of $5.4 million in royalties on $42.4 million in sales of Vimovo at Horizon Pharma (HZNP) in the U.S. and $19.7 million in sales at AstraZeneca (AZN) outside …

  • GOVX: Second Quarter Financials Reported with a Conservative Cash Burn Zacks Small Cap Research - Thu, Aug 7, 2014 12:30 PM EDT

    On August 7, 2014, GeoVax Labs (GOVX) announced its financial results for the second quarter ended June 30, 2014 and provided a clinical development update.  Grant revenues were $180,441 for 2Q14, which was related to grants from the NIH in support of its HIV/AIDS vaccine development programs. For 2Q13, GeoVax reported …

  • PRGB: Q2 Results: No Surprises, Maintaining Outperform Rating Zacks Small Cap Research - Wed, Aug 6, 2014 6:00 PM EDT

    Protea sold one LAESI unit in Q2 2014 and two units through the first half of the current year.  Importantly, the company is already starting to see revenue growth coming from their services and information related businesses, which is what we expect to be the sustainable long-term drivers of the top line. Also, LAESI …

  • VNRX: Initial Data From Colon Cancer Study Should Be Forthcoming Zacks Small Cap Research - Wed, Aug 6, 2014 9:00 AM EDT

    On the operational front, the last few quarters have been particularly productive for VNRX – mostly relating to additional positive clinical data and commencing additional clinical studies.  Recent positive data from the Bonn University and CHU Dinant Godinne studies, indicating high specificity and sensitivity of the NuQ …

  • ACAD: Acadia On Track With Pimavanserin Development Program Zacks Small Cap Research - Wed, Aug 6, 2014 8:30 AM EDT

    On August 5, 2014, Acadia Pharmaceuticals (ACAD) reported financial results for the second quarter 2014 ended June 30, 2014. Revenues in the quarter totaled $28,000 compared to $451,000 for the second quarter of 2013, with the decrease primarily due to the conclusion of Acadia’s 2003 research collaboration with Allergen …

  • S&W Seed (SANW) announced on August 05, 2014 that it has contracted the  production of its high yield California alfalfa seed varieties in about 1,000 acres of land in Australia. The costs of production are lower in Australia than in California. The cost of shipping seeds from Australia to the Middle East are about the …

  • Threshold (THLD): Strong Balance Sheet Supports Scheduled Clinical Advancement Zacks Small Cap Research - Tue, Aug 5, 2014 10:00 AM EDT

    By Grant Zeng, CFA NASDAQ:THLD Threshold Exited Second Quarter with a Strong Balance Sheet On Aug 1, 2014, Threshold Pharmaceuticals (NASADQ:THLD) reported second quarter financial results ended June 30, ...

  • Soligenix (SNGX) is a clinical stage biopharmaceutical company developing therapeutics for the treatment of inflammatory diseases as well as biodefense vaccines and therapies. On August 1st, 2014, the company announced that the National Institute of Allergy and Infectious Diseases (NIAID) will provide an additional $2.1 …

  • AMBS: Why I'm Still Optimistic On LymPro and Amarantus Bio Zacks Small Cap Research - Mon, Aug 4, 2014 10:40 AM EDT

    Amarantus BioScience Holdings (AMBS) stock has been on a wild ride over the past two months. The shares were trading at only 7 cents in May 2014 before news broke that the company would be presenting data on LymPro, the company's Alzheimer's disease (AD) blood test, at two medical conferences in July 2014. Below is a …

  • CYRX: Another Great Quarter. DHL Deal A Big Win Zacks Small Cap Research - Mon, Aug 4, 2014 10:30 AM EDT

    CryoPort Inc (CYRX) announced results for their 2015 fiscal first quarter.  Results continue to come in within our expectations with revenue climbing nicely q-to-q.  Q1 marked the 11th straight quarter of sequential revenue growth and we expect this to continue to be the case for the foreseeable future as the top line is …

  • Dejour Energy (DEJ): Zacks ups price target on Roan Creek Resource Estimate Zacks Small Cap Research - Sun, Aug 3, 2014 11:00 PM EDT

    Dejour Energy (DEJ.TO) (DEJ) recently announced two milestone events: the commencement of the 2014 Kokopelli drilling program and an initial Contingent and Prospective Resource estimate for the Roan Creek leasehold. Utilizing the Best Estimates (P-50), we estimate that the Contingent and Prospective Resources adds approximately …

  • CDTI: Changing of the Guard Zacks Small Cap Research - Sun, Aug 3, 2014 4:20 PM EDT

    By Ian Gilson, PhD, CFA NASDAQ:CDTI When companies change CEOs it is not unusual for there to be a realignment of responsibilities and  changes in senior management, as well as changes in strategic directions. ...

Next >>